Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 9;10(4):670.
doi: 10.3390/jcm10040670.

Management of Lupus Nephritis

Farah Tamirou  1 , Frédéric A Houssiau  1
Affiliations
Review

Management of Lupus Nephritis

Farah Tamirou et al. J Clin Med. .

Abstract

Lupus nephritis (LN) is a frequent and severe manifestation of systemic lupus erythematosus. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease. To improve the prognosis of LN, recent data suggest that we should (i) modify our treat-to-target approach by including, in addition to a clinical target, a pathological target and (ii) switch from conventional sequential therapy to combination therapy. Here, we also review the results of recent controlled randomized trials.

Keywords: combination therapy; lupus nephritis; repeat kidney biopsy; treat-to-target approach.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
REBIOLUP flowchart.
See this image and copyright information in PMC

References

    1. Rovin B.H., Stillman I. Kidney. In: Lahita R., editor. Systemic Lupus Erythematosus. 5th ed. Academic Press; San Diego, CA, USA: 2011. pp. 769–814.
    1. Wang H., Ren Y.L., Chang J., Gu L., Sun L.Y. A systematic review and meta-analysis of prevalence of biopsy-proven lupus nephritis. Arch. Rheumatol. 2017;33:17–25. doi: 10.5606/ArchRheumatol.2017.6127. - DOI - PMC - PubMed
    1. Seligman V.A., Suarez C., Lum R., Inda S.E., Lin D., Li H., Olson J.L., Seldin M.F., Criswell L.A. The Fcgamma receptor IIIA-158F allele is a major risk factor for the development of lupus nephritis among Caucasians but not non-Caucasians. Arthritis Rheum. 2001;44:618–625. doi: 10.1002/1529-0131(200103)44:3<618::AID-ANR110>3.0.CO;2-R. - DOI - PubMed
    1. Lech M., Anders H.J. The pathogenesis of lupus nephritis. J. Am. Soc. Nephrol. 2013;24:1357–1366. doi: 10.1681/ASN.2013010026. - DOI - PMC - PubMed
    1. Tojo T., Friou G.J. Lupus nephritis: Varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science. 1968;161:904–906. doi: 10.1126/science.161.3844.904. - DOI - PubMed

LinkOut - more resources